DelveInsight’s “Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.
Discover which therapies are expected to grab the Dravet Syndrome Market Share @ https://www.delveinsight.com/sample-request/dravet-syndrome-market
Key Takeaways from the Dravet Syndrome Market Report
- In April 2026, Jazz Pharmaceuticals presented research on EPIDIOLEX (cannabidiol) Oral Solution on Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting.
- In March 2026, Stoke Therapeutics and Biogen reported in The New England Journal of Medicine that their investigational RNA therapy zorevunersen showed early evidence of potential disease modification in Dravet syndrome, based on Phase I/IIa and ongoing extension study results.
- In March 2026, Encoded Therapeutics announced the successful completion of its Initial Comprehensive Multidisciplinary Regenerative Medicine Advanced Therapy (RMAT) meeting with the US Food and Drug Administration (FDA), and alignment on the pivotal study design supporting the company’s planned BLA submission for ETX101, an AAV9-based gene regulation therapy designed as a one-time, disease-modifying treatment for SCN1A+ Dravet syndrome.
- The increase in Dravet Syndrome Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
- As per DelveInsight analysis, the Dravet Syndrome Market is anticipated to witness growth at a notable CAGR during the forecast period (2026-2036).
- The leading Dravet Syndrome Companies such as Stoke Therapeutics, Biogen, Longboard Pharmaceuticals, Harmony Biosciences, Encoded Therapeutics, Jazz Pharmaceuticals, UCB, Zogenix, BIOCODEX, and others.
- Promising Dravet Syndrome therapies are Zorevunersen (STK-001), ETX101, Bexicaserin (LP352), Clemizole Hydrochloride (EPX-100), Cannabidiol (EPIDIOLEX/EPIDYOLEX), Fenfluramine (FINTEPLA), Stiripentol (DIACOMIT), and others.
Stay ahead in the Dravet Syndrome Therapeutics Market with DelveInsight’s Strategic Report @ Dravet Syndrome Market Outlook
Dravet Syndrome Overview
Dravet syndrome is a rare, severe form of genetic epilepsy characterized by intense seizure activity and developmental delays that typically begins in infancy. Previously referred to as Severe Myoclonic Epilepsy of Infancy (SMEI), the condition significantly impacts patients’ quality of life, often causing treatment-resistant seizures, cognitive impairment, behavioral issues, and motor difficulties that persist throughout life.
The disorder involves complex pathophysiology related to mutations in the SCN1A gene, which encodes a voltage-gated sodium channel protein. Approximately 85% of patients with Dravet syndrome carry such mutations, leading to dysfunction in neuronal sodium channels. Patients typically experience symptoms including prolonged fever-triggered seizures beginning between 2 and 15 months of age, multiple seizure types, developmental delays, and physical manifestations such as motor and speech difficulties.
Diagnosis of Dravet syndrome follows established clinical criteria combined with genetic testing, with careful assessment to distinguish it from other epilepsy syndromes and ensure appropriate treatment selection. Current treatment approaches combine anti-seizure medications including fenfluramine, cannabidiol, stiripentol, valproate, and clobazam, with avoidance of sodium-channel blockers. Management also includes trigger control, rescue medications for status epilepticus, and long-term supportive care addressing developmental, behavioral, and safety needs.
Epidemiology Insights for Dravet Syndrome
DelveInsight’s epidemiology analysis evaluates the diagnosed and prevalent patient population across the 7MM from 2022 to 2036. The study segments data by prevalence, mutation status, age distribution, gender distribution, and diagnostic status.
- Overall Prevalence: The total diagnosed prevalence of Dravet syndrome in the 7MM comprised approximately 25,600 cases in 2025, with the patient pool reflecting significant disease burden across major markets. The prevalence is estimated to range from 1 in 20,000 to 1 in 40,000 individuals.
- Severity Stratification: About 3-8% of infants with seizures in the first year may be diagnosed with Dravet syndrome. Patients experience treatment-resistant seizures with many remaining poorly controlled despite available treatments, requiring intensive, lifelong intervention.
- Gender-Based Trends: Dravet syndrome shows distinct gender distribution with a male-to-female ratio of approximately 2:1, demonstrating higher prevalence in males compared to females.
- Chronic Disease Management: The chronic, lifelong nature of Dravet syndrome requires sustained treatment and comprehensive multidisciplinary care, supporting ongoing demand for effective therapeutic options. Mortality affects up to 20% of children and adolescents before adulthood.
Explore more about Dravet Syndrome Epidemiology @ Dravet Syndrome Market Dynamics
Drug Uptake and Pipeline Advancements
The Dravet syndrome treatment landscape includes both established marketed therapies and emerging pipeline candidates progressing through late and mid-stage clinical development.
Leading Marketed Therapies:
- Cannabidiol (EPIDIOLEX/EPIDYOLEX) – Jazz Pharmaceuticals: Approved prescription, plant-derived cannabis-based medicine administered as oral solution. Approved in the US (2018) and EU (2019) for seizures associated with Dravet syndrome.
- Fenfluramine (FINTEPLA) – UCB/Zogenix: Low-dose fenfluramine oral solution approved in the US (2020), EU (2020), and Japan (2022). Acts as 5-HT2B receptor agonist with serotonin pathway modulation.
- Stiripentol (DIACOMIT) – BIOCODEX: Approved in US (2018) targeting GABA-A receptors for seizures associated with Dravet syndrome.
- Additional marketed products and off-label anti-seizure medications currently available for Dravet syndrome management.
Emerging Pipeline Assets:
- Zorevunersen (STK-001) – Stoke Therapeutics/Biogen: Phase III antisense oligonucleotide designed to upregulate NaV1.1 protein expression by targeting the SCN1A gene. Granted FDA Breakthrough Therapy Designation and rare pediatric disease designation.
- ETX101 – Encoded Therapeutics: Phase I/II AAV9-based gene regulation therapy designed as one-time, disease-modifying treatment for SCN1A+ Dravet syndrome. Recently granted FDA Breakthrough Therapy Designation.
- Bexicaserin (LP352) – Longboard Pharmaceuticals: Phase III oral 5-hydroxytryptamine 2c receptor superagonist.
- Clemizole Hydrochloride (EPX-100) – Harmony Biosciences: Phase III oral small molecule targeting central 5-HT2 serotonin receptors.
- Development activities focused on addressing unmet medical needs including disease-modifying SCN1A-targeted therapies and treatments with improved safety profiles.
The pipeline therapies are anticipated to enter the market during the forecast period, potentially reshaping treatment paradigms and competitive dynamics with gene-targeted and precision medicine approaches.
Dravet Syndrome Market Drivers and Challenges
Dravet Syndrome Market Drivers
- Rising awareness of Dravet syndrome and reduced diagnostic delays through improved genetic testing
- Incremental healthcare spending across global markets supporting expanded access to specialized epilepsy treatment
- Growing patient population with increasing prevalence, particularly among children aged ≤16 years (approximately 22,600 diagnosed prevalent cases in the US in 2025)
- Better understanding of SCN1A gene dysfunction and disease pathogenesis enabling development of targeted therapeutics
- Expansion of reimbursement coverage for rare disease treatments
- Rising opportunities in precision and mechanism-based therapies including gene therapies, antisense oligonucleotides, and novel neuromodulators
Dravet Syndrome Market Barriers
- Limited availability of curative or disease-modifying therapies targeting underlying SCN1A dysfunction
- Challenges in patient diagnosis due to symptom overlap with other epilepsy syndromes and progressive evolution of clinical features
- Refractory seizures with many patients remaining poorly controlled despite combination therapy
- High burden of cognitive, behavioral, and neurodevelopmental comorbidities requiring comprehensive management
- Safety issues with current treatments including drug interactions and side effects
- High development costs for novel gene therapies and precision medicines
- Genetic heterogeneity as not all patients carry SCN1A mutations, complicating targeted therapy development
- Limited access to specialized genetic testing and low clinical awareness among healthcare providers
Dravet Syndrome Competitive Landscape
The Dravet syndrome treatment market features both established pharmaceutical leaders and companies developing innovative gene-targeted and disease-modifying therapeutic approaches.
Key Dravet Syndrome Companies:
- Stoke Therapeutics
- Biogen
- Longboard Pharmaceuticals
- Harmony Biosciences
- Encoded Therapeutics
- Jazz Pharmaceuticals
- UCB
- Zogenix
- BIOCODEX
- Additional companies developing targeted therapeutics for rare epilepsies
These organizations are actively pursuing clinical development programs, strategic collaborations, regulatory milestone achievements, and licensing activities to strengthen their market positioning in the rare genetic epilepsy treatment space.
Scope of the Dravet Syndrome Market Report
- Coverage – 7MM
- Study period – 2022-2036
- Forecast period – 2026-2036
- Dravet Syndrome Companies – Stoke Therapeutics, Biogen, Longboard Pharmaceuticals, Harmony Biosciences, Encoded Therapeutics, Jazz Pharmaceuticals, UCB, Zogenix, BIOCODEX, and others.
- Dravet Syndrome Market Dynamics: Dravet Syndrome Market Drivers and Barriers
- Dravet Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives
- Epidemiology Segmentation: Total Diagnosed Prevalent Cases, Mutation-specific Cases, Age-specific Cases, Gender-specific Cases
Discover more about Dravet Syndrome Drugs in development @ Dravet Syndrome Clinical Trials Assessment
Table of Content
- Key Insights
- Report Introduction
- Executive Summary
- Key Events
- Epidemiology and Market Forecast Methodology
- Dravet Syndrome Market Overview at a Glance
- Disease Background and Overview of Dravet Syndrome
- Treatment Guidelines for Dravet Syndrome
- Epidemiology and Patient Population of Dravet Syndrome
- Patient Journey of Dravet Syndrome
- Marketed Therapies
- Emerging Therapies
- Dravet Syndrome: 7MM Analysis
- Unmet Needs of Dravet Syndrome
- SWOT Analysis of Dravet Syndrome
- KOL Views of Dravet Syndrome
- Market Access and Reimbursement of Dravet Syndrome
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
